SCHEMBL20535344

SCHEMBL20535344

O=Cc1ccc(SCc2ccc(Cl)cc2)cc1Br

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.53
MAPT P10636 4/20 0.53
NPSR1 Q6W5P4 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
HTT P42858 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
MAOB P27338 5/20 0.49
MAOA P21397 4/20 0.49
MEN1 O00255 7/20 0.47
KMT2A Q03164 7/20 0.47
ALDH1A1 P00352 3/20 0.47
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
RHEB Q15382 1/20 0.45
GAA P10253 2/20 0.42
MGAM O43451 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
DAO P14920 1/20 0.42
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31733497 0.85 CYP3A4 (0.49) LMNAMAPTNPSR1SMN1; SMN2HTT
SCHEMBL23709927 0.84 LMNA (0.51) LMNAMAPTNPSR1SMN1; SMN2HTT
SCHEMBL2279052 0.80 TDP1 (0.44) LMNAMAPTNPSR1SMN1; SMN2HTT
SCHEMBL21331846 0.74 ALDH1A1 (0.61) LMNAMAPTNPSR1SMN1; SMN2HTT
SCHEMBL16706976 0.74 LMNA (0.46) LMNAMAPTSMN1; SMN2HTTMAOA
SCHEMBL380731 0.73 TDP1 (0.61) LMNAMAPTSMN1; SMN2ALDH1A1TDP1
SCHEMBL83796 0.73 MEN1 (0.80) LMNAMAPTNPSR1SMN1; SMN2MAOB
SCHEMBL31733523 0.73 MAOB (0.47) LMNAMAPTNPSR1SMN1; SMN2HTT
SCHEMBL16295776 0.73 MAOB (0.47) LMNAMAPTNPSR1SMN1; SMN2HTT
SCHEMBL21362601 0.72 PRKDC (0.41) LMNAMAPTSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 US disclosed
WO-2018191146-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF RHEB, KRAS, NRAS LMNA 4243/4885MAPT 4119/4885NPSR1 4530/4885
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof RHEB, GDI2, KRAS LMNA 2918/4885MAPT 2840/4885NPSR1 4567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.